Evaluation of different concentrations of imatinib on the viability of Leishmania major: An In Vitro study

Moslehi, Mohsen; Namdar, Fatemeh; Esmaeilifallah, Mahsa; Hossein Hejazi, Seyed; Sokhanvari, Fatemeh; Siadat, Amir Hossein; Hosseini, Seyed Mohsen; Iraji, Fariba

Evaluation of different concentrations of imatinib on the viability of Leishmania major: An In Vitro study

Authors

¹ Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

² Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

³ Skin Diseases and Leishmaniasis Research Center; Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

⁴ Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran

⁵ Department of Biostatistics and Epidemiology, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Leishmaniasis is an infectious disease caused by an intracellular parasite of Leishmania and is transmitted through the female sandflies bite and may lead to severe skin lesions. Although drugs such as antimony compounds are available, their side effects such as toxicity, low efficacy, and emergence of resistance have raised the importance of effective replacement. Imatinib, as an inhibitor of tyrosine kinase (TK) of Leishmania, stops abnormal function of TK such as Bcr-Abl through assembling into transmembrane pores in a sterol-dependent manner. Hence, the evaluation of killing effects of different concentrations of imatinib against Leishmania major amastigotes and promastigotes in vitro were the objectives of the present study.Materials and Methods: The killing effects of different concentrations of imatinib (25, 50, and 100 μg) and 25 μg amphotericin B (as positive control) were evaluated against RPMI 1640-cultured promastigotes and the amastigote/macrophage model by MTS cell proliferation assay kit (ab197010) and Giemsa staining method during 24, 48, and 72 h. Results: The results showed anti-Leishmania effect of imatinib in concentration and time-dependent manner. The lowest number of live promastigotes and amastigotes were obtained due to treat with 100 μ/ml imatinib at 72 h. Furthermore, 100 μg concentration of imatinib had the same effect as 25 μg amphotericin B on both L. major promastigotes and amastigotes (P < 0.001). Conclusion: The anti-Leishmania effect of imatinib was confirmed by MTS and direct microscopy. Further study is recommended for evaluating possible therapeutic effects of imatinib on leishmaniasis in vivo.

Keywords

References

1.	Mohaghegh M, Fata A, Salehi G, Berenji F, Bazzaz MM, Rafatpanah H, et al. Molecular identification of Leishmania species using samples obtained from negative stained smears. Iran J Parasitol 2013;8:337-41.
2.	Hashemi N, Mohaghegh M, Hashemi M, Azami M, Mortazavidehkordi N, Hashemi C, et al. PCR-RFLP diagnosis and characterization of Leishmania species causing human cutaneous leishmaniasis and evaluation of treatment times with glucantime in these patients. Trop Biomed 2016;33:689-96.
3.	Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012;7:e35671.
4.	Mirzaei F, Bafghi AF, Mohaghegh MA, Jaliani HZ, Faridnia R, Kalani H. In vitro anti-leishmanial activity of Satureja hortensis and Artemisia dracunculus extracts on Leishmania major promastigotes. J Parasit Dis 2016;40:1571-4.
5.	Sacks D, Kamhawi S. Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis. Annu Rev Microbiol 2001;55:453-83.
6.	Manning G. Genomic overview of protein kinases. WormBook 2005;13 (1)-9.
7.	Chen MJ, Dixon JE, Manning G. Genomics and evolution of protein phosphatases. Sci Signal 2017;10. pii: eaag1796.
8.	Borba JV, Silva AC, Ramos PI, Grazzia N, Miguel DC, Muratov EN, et al. Unveiling the kinomes of Leishmania infantum and L. Braziliensis empowers the discovery of new kinase targets and antileishmanial compounds. Comput Struct Biotechnol J 2019;17:352-61.
9.	Zhang ZY. Structure, mechanism, and specificity of protein-tyrosine phosphatases. Curr Top Cell Regul 1997;35:21-68.
10.	Radha V, Nambirajan S, Swarup G. Association of lyn tyrosine kinase with the nuclear matrix and cell-cycle-dependent changes in matrix-associated tyrosine kinase activity. Eur J Biochem 1996;236:352-9.
11.	Napier RJ, Norris BA, Swimm A, Giver CR, Harris WA, Laval J, et al. Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. PLoS Pathog 2015;11:e1004770.
12.	Lebeis SL, Kalman D. Aligning antimicrobial drug discovery with complex and redundant host-pathogen interactions. Cell Host Microbe 2009;5:114-22.
13.	Dan-Goor M, Nasereddin A, Jaber H, Jaffe CL. Identification of a secreted casein kinase 1 in Leishmania donovani: Effect of protein over expression on parasite growth and virulence. PLoS One 2013;8:e79287.
14.	Shadab M, Ali N. Evasion of host defence by Leishmania donovani: Subversion of signaling pathways. Mol Biol Int 2011;2011:343961.
15.	Cunha MA, Leão AC, de Cassia Soler R, Lindoso JA. Efficacy and safety of liposomal amphotericin B for the treatment of mucosal leishmaniasis from the new world: A retrospective study. Am J Trop Med Hyg 2015;93:1214-8.
16.	Wortmann G, Zapor M, Ressner R, Fraser S, Hartzell J, Pierson J, et al. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2010;83:1028-33.
17.	Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience. Blood 2012;119:1981-7.
18.	Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. Chemother Res Pract 2014;2014:357027.
19.	Hanks SK, Quinn AM, Hunter T. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 1988;241:42-52.
20.	Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits thein vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 2003;17:1713-21.
21.	Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA, Bornmann W, et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 2011;10:475-85.
22.	O'Connell EM, Kamenyeva O, Lustigman S, Bell A, Nutman TB. Defining the target and the effect of imatinib on the filarial c-abl homologue. PLoS Negl Trop Dis 2017;11:e0005690.
23.	Katz N, Couto FF, Araújo N. Imatinib activity on Schistosoma mansoni. Mem Inst Oswaldo Cruz 2013;108:850-3.
24.	Cleghorn LA, Woodland A, Collie IT, Torrie LS, Norcross N, Luksch T, et al. Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3. ChemMedChem 2011;6:2214-24.
25.	Sanderson L, Yardley V, Croft SL. Activity of anti-cancer protein kinase inhibitors against Leishmania spp. J Antimicrob Chemother 2014;69:1888-91.
26.	Wetzel DM, McMahon-Pratt D, Koleske AJ. The abl and arg kinases mediate distinct modes of phagocytosis and are required for maximal Leishmania infection. Mol Cell Biol 2012;32:3176-86.
27.	Orsolic N, Golemovic M, Quintás-Cardama A, Scappini B, Manshouri T, Chandra J, et al. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Cancer Sci 2006;97:952-60.
28.	Tegazzini D, Díaz R, Aguilar F, Peña I, Presa JL, Yardley V, et al. Areplicativein vitro assay for drug discovery against Leishmania donovani. Antimicrob Agents Chemother 2016;60:3524-32.
29.	Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008;49:615-9.
30.	Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang YS. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer 2018;17:36.
31.	Das P, Alam MN, Paik D, Karmakar K, De T, Chakraborti T. Protease inhibitors in potential drug development for leishmaniasis. Indian J Biochem Biophys 2013;50:363-76.
32.	Zhang N, Kima PE. Leishmania infection engages non-receptor protein kinases differentially to persist in infected hosts. Front Immunol 2016;7:146.
33.	Simões-Silva MR, De Araújo JS, Peres RB, Da Silva PB, Batista MM, De Azevedo LD, et al. Repurposing strategies for chagas disease therapy: The effect of imatinib and derivatives against Trypanosoma cruzi. Parasitology 2019;146:1006-12.

Advanced Biomedical Research